Hospital Medicine
Physician discussions on inpatient care, transitions of care, diagnostic reasoning, and hospital-based protocols.
Recent Discussions
When should metformin be stopped before surgery and when is it considered safe to resume?
Immediate release metformin can generally be continued up until the day of surgery unless there is preoperative renal compromise such that estimated GFR drops below 30 cc/min. Extended release metformin that is taken in the evening can be held on the night prior to surgery. If the patient is well wi...
Would you consider pharmacotherapy (i.e., GLP1-agonist) or behavioral/nutrition interventions alone in a patient with a remote history of a restrictive eating disorder now presenting with obesity and metabolic complications?
I would consider both pharmacotherapy and lifestyle interventions in a patient with a remote history of an eating disorder. BUT, this should be done by obesity medicine specialists who are better trained to evaluate the patient, prescribe appropriate measures, and monitor the patient carefully. Alte...
How do you use cardiac POCUS to potentially defer formal echocardiogram in patients presenting with an acute pulmonary embolism?
In patients with acute PE, cardiac ultrasound is useful in risk stratification and identification of patients at higher risk of short-term mortality and complications. Signs to look for on POCUS are: RV dilatation (RV>LV on apical 4-chamber view), McConnell Sign (hyperkinetic RV apex with hypokineti...
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
There doesn't seem to be any evidence that GLP-1 RA would increase the risk of CV disease. Biologically, the benefits that have been shown in patients without Diabetes (the SELECT trial) should still be applicable for patients with Diabetes Type 1.The trials that didn't show much efficacy in glucose...
When managing patients with suspected MASLD, what specific criteria or findings would prompt you to refer them to hepatology?
In patients with suspected MASLD, I consider referral to hepatology when there is evidence of fibrosis by elastography or if I don't see improvements in related parameters with weight loss and/or medical therapies (GLP1-related meds, SGLT2i, TZDs).
What is your approach to initiation of mirtazapine for appetite stimulation and depression in older adults, both in terms of starting dose and titration?
I consider initiation of mirtazapine for older adults who could benefit from at least two of the three potential effects of mirtazapine - improvement of mood, appetite, and/or sleep. I always start at a low dose of 7.5 mg nightly, potentially uptitrating to 15 mg nightly after a week or two if the m...
Can patients "age out" of screening colonoscopies if, on their last colonoscopy prior to turning 76, they had tubular adenomas?
How long ago was the last colonoscopy? How many adenomas? How old is the patient now? State of health and expected longevity? What does the patient want? Frankly, at this point, I think I’d probably be content with an annual FIT.
What is your preferred method for subclinical CAD screening prior to initiation of class IC antiarrhythmic drugs for atrial fibrillation?
Flecainide and propafenone are the IC agents in use for atrial fibrillation. Encainide and moricizine were predominantly used for ventricular arrhythmias and encainide was pulled a long time ago due to proarrhythmia concerns and I believe Ethmozine stopped being marked many years ago.The CAST trial ...
Is there a particular PVC/NSVT burden on inpatient telemetry in which you would consider discharging a patient with a LifeVest post-STEMI with newly reduced LVEF <35% while optimizing GDMT?
The PVC/NSVT burden is not part of the equation for post-STEMI LifeVest. The guidelines clearly state that if you have an EF of <35% and are within 40 days of an MI, or any revascularization within the past 90 days, the wearable defibrillator is a class IIb indication while optimizing GDMT. If the p...
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
We practice in an area with a good bit of blastomycosis and rarely see a positive Blastomyces antibody, even in patients with culture-proven blastomycosis. The newer EIA antibody that MiraVista lab is doing may be more reliable. If the prior granulomatous lung disease has been worked up with negativ...